1. Jiang, Peng, Gu, Shengqing, Pan, Deng, Wucherpfennig, Kai W, Liu, X Shirley. 2018. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. In Nature medicine, 24, 1550-1558. doi:10.1038/s41591-018-0136-1. https://pubmed.ncbi.nlm.nih.gov/30127393/
2. Ibáñez-Molero, Sofía, van Vliet, Alex, Pozniak, Joanna, Wessels, Lodewyk, Peeper, Daniel S. 2022. SERPINB9 is commonly amplified and high expression in cancer cells correlates with poor immune checkpoint blockade response. In Oncoimmunology, 11, 2139074. doi:10.1080/2162402X.2022.2139074. https://pubmed.ncbi.nlm.nih.gov/36465485/
3. Harada, Mamoru, Kotani, Hitoshi, Iida, Yuichi, Yoshikawa, Kazuhiro, Uemura, Hirotsugu. 2024. Hypoxia-related carbonic anhydrase 9 induces serpinB9 expression in cancer cells and apoptosis in T cells via acidosis. In Cancer science, 115, 1405-1416. doi:10.1111/cas.16133. https://pubmed.ncbi.nlm.nih.gov/38413363/
4. van der Burgh, Robert, Meeldijk, Jan, Jongeneel, Lieneke, van Gijn, Mariëlle, Boes, Marianne. . Reduced serpinB9-mediated caspase-1 inhibition can contribute to autoinflammatory disease. In Oncotarget, 7, 19265-71. doi:10.18632/oncotarget.8086. https://pubmed.ncbi.nlm.nih.gov/26992230/